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Abstract: Radiotherapy (RT) and transoral laser microsurgery (TLM) represent the main treatment
modalities for early glottic carcinoma. Local failure is notoriously more frequent in T1b glottic
cancer in comparison to T1a and T2 tumors. In this scenario, the role of anterior commissure (AC)
involvement is still controversial. The aim of the present study was therefore to determine its potential
prognostic power in worsening patients’ survival and outcomes. We categorized different tumor
glottic fold locations with respect to the involvement of one (T1a) or both vocal cords, with or without
AC involvement. We analyzed a retrospective cohort of 74 patients affected by Stage I glottic cancer,
treated between 2011 and 2018 by TLM or RT at a single academic institution. There were 22 T1a (30%)
and 52 T1b (70%) cases. The median follow-up period was 30 months (mean, 32.09 ± 18.738 months;
range, 12–79). Three-year overall survival (OS), disease-specific survival (DSS), recurrence-free
survival (RFS), and laryngectomy-free survival (LFS) were compared according to tumor location,
extension, and cT category. According to both uni- and multivariate analyses, an increased risk
for recurrence in T1b with AC involvement and T1a tumors was 7.31 and 9.45 times, respectively
(p-values of 0.054 and 0.030, respectively). Among the 17 recurrences, T1b with AC involvement
experienced 15 tumor relapses (88.2%), thus significantly affecting both the RFS and LFS in comparison
to the other two tumor subcategories (T1a, p = 0.028 and T1b without AC involvement, p = 0.043).
The deteriorating prognosis in the presence of AC involvement likely reflects the need to power the
hazard consistency and discrimination of the T1b category when associated with such a risk factor,
thus deserving an independent T category.
Keywords: early glottic cancer; anterior commissure involvement; prognosis; independent
prognostic factor
1. Introduction
Glottic squamous cell carcinoma (SCC) represents about 75% of laryngeal malignancies [1] and
arises from the glottic plane which, according to the staging manual of the American Joint Committee
on Cancer (AJCC), includes three different anatomical subsites: the vocal cords, anterior commissure
(AC), and posterior commissure (PC) [2].
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The five-year disease-specific survival (DSS) of T1 glottic SCC ranges between 94% and 100%,
with a five-year local control of 84% [3,4]. The AC is rarely the site of origin of these tumors, but it is
involved in up to 20% of early glottic cancers [5,6]. The AC’s complex anatomy constitutes a single
subsite of the larynx which, according to its embryonic origin, presents a vertical extension [7] as well
as a locus minoris resistentiae due to the absence of the inner perichondrium in correspondence to the
intermediate lamina of the thyroid cartilage [8,9]. In this setting, the AC has always been the object of
anatomic, diagnostic, and therapeutic controversies in laryngeal oncology. Furthermore, the pooled
difference in five-year local recurrence rates between T1 glottic SCC without (T1a) and with (T1b) AC
involvement has been reported to rise up to 12%, regardless of the type of treatment adopted (either
radiotherapy (RT) or transoral laser microsurgery (TLM), thus making the presence of AC involvement
an independent negative prognostic factor for Stage I glottic lesions [10–15]. Although several studies
have shown a significant association between AC involvement and a higher recurrence rate of glottic
SCC [8,10–17], the specific value of the AC anatomical partition is not taken into account by the current
TNM staging system as a structure whose involvement plays an independent prognostic role [18].
Since the binary variables for AC involvement has led to inconsistent results in the literature [10,19],
the purpose of this study was to propose a more detailed stratification for tumors involving the AC,
in order to better assess its prognostic role in early glottic carcinomas and consequently evaluate its
effect on survival. The final aim was to understand if early glottic SCC with AC involvement does
deserve a different staging category.
2. Materials and Methods
2.1. Study Population
A retrospective study on patients treated for T1a and T1b glottic SCC between June 2011 and
June 2018 at the Departments of Otorhinolaryngology—Head and Neck Surgery and Radiotherapy,
University of Florence, Italy, was carried out. This retrospective observational study was approved by
the local Ethical Committee with protocol number 16208_oss, and all the procedures were conducted
in accordance to the Helsinki Declaration of 1975, as revised in 1983. All of the patients’ clinical
charts were reviewed and tumors retrospectively restaged according to the 8th Edition of the AJCC
staging system [18]. All the participants provided informed consent before undergoing curative
treatment, either TLM or RT. The indications for both therapeutic approaches included the presence of a
biopsy-proven glottic primary SCC, staged as cT1aN0 or cT1bN0 (Stage I) according to the preoperative
fiberoptic evaluation, radiological imaging by CAT (computed assisted tomography) and/or MRI
(magnetic resonance imaging) with contrast medium administration, and intraoperative endoscopic
assessment performed to get a biopsy of the lesion. All patients and their therapeutic options were
discussed and shared among the members of the local multidisciplinary team (MDT).
The exclusion criteria were as follows: pre- and/or intraoperative clinical and radiological evidence
of glottic SCC different from Stage I; PC involvement; patients previously treated for other head and
neck cancers or already submitted to any kind of head and neck surgical procedures, including RT
and/or CRT (chemoradiation); patients who did not consent to be enrolled in the study; and patients
with incomplete clinical chart records and missing data.
The patients’ demographics, including their Charlson comorbidity index (CCI) [20], tumor and
treatment characteristics, and survival rates, were recorded and reviewed in a single dedicated database.
All patients underwent diagnostic preoperative assessment including videolaryngoscopy
coupled with narrow-band imaging (NBI) (Olympus Medical Systems Corporation, Tokyo, Japan),
and intraoperative panendoscopy with 0◦, 30◦, and 70◦ rigid telescopes, under general anesthesia in
the operating room. This allowed us to carefully examine the AC, with the specific aim of confirming or
excluding its potential involvement. In particular, special attention was devoted to 70◦ rigid endoscopy
to rule out potential subcommissural tumor extension. In the case of multiple glottic lesions, separate
biopsies were performed to confirm if they were malignant in nature or not. When surgical margins
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after TLM were close or positive (especially in the case of deep margin involvement), further re-excision
was generally planned. In selected cases, a wait-and-see policy was adopted after patient counseling if
the excision was believed to be radical and close/positive margins interpreted as an artifact of laser
diathermal effect or surgical specimen processing. Adjuvant radiotherapy (RT) was administered in
the presence of clinical and/or pathological factors that increase the risk of tumor recurrence after
primary surgical treatment.
On the other hand, primary RT was chosen upon patient request, major concerns regarding vocal
outcomes, in cases with a preoperative Laryngoscore ≥9 [21], or whenever unfavorable laryngeal
exposure had been confirmed during the pretreatment general anesthesia for bioptic purposes alone.
In these cases, a CT scan (Big Bore, Philips Medical Systems, Cleveland, OH, USA) was acquired at
a 3-mm slice width for radiation treatment planning. Personalized thermoplastic head, neck, and
shoulder masks were created for all patients. A three-dimensional, conformal technique was employed:
radiation was delivered by means of opposing lateral fields with proper wedge filters using 6 MV
photons. The clinical target volume (CTV) consisted of the whole larynx. A 5-mm CTV to planning
target volume (PTV) was applied in order to compensate for potential systematic and random errors.
The prescribed dose for the PTV was 70 Gray (Gy) given in 35 fractions of 2 Gy in 7 weeks.
2.2. Novel Classification Proposal
To better assess the role of AC involvement in affecting Stage I survival and outcomes, we applied
a novel classification system for T1 glottic SCC. AC involvement here refers to all of Rucci’s categories
except for the AC0 class [7]. Our proposal is therefore articulated as follows:
1. T1a, tumor limited to one vocal cord, without AC involvement, with normal vocal cord mobility
(Figure 1);
2. T1b without AC, tumor involving both vocal cords, without AC involvement, with normal vocal
cord mobility (Figure 2);
3. T1b with AC, tumor involving one or both vocal cords, with AC involvement, with normal vocal
cord mobility (Figure 3).
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2.3. Statistical Analysis
The following endpoints were considered: overall survival (OS), defined as the time between
the date of surgery and the date of death/last visit; disease-specific survival (DSS), defined as the
time between the date of surgery and the date of cancer-related death/last visit; recurrence-free
survival (RFS), defined as the time between the date of surgery and the date of recurrence/last visit;
and laryngectomy-free survival (LFS), defined as the time between the date of surgery and the date of
total laryngectomy/death/last visit.
The influence of the three different abovementioned tumor categories on the prognosis was
estimated through the computation of the OS, DSS, RFS, and LFS curves using the Kaplan–Meier
method and comparison by the log-rank test for the dichotomic variables. Multivariate analysis was
performed using the Cox proportional hazard models and expressed as hazard ratios (HRs) with 95%
confidence intervals (CIs).
All the tests were 2-tailed, and p-values < 0.05 were considered to be statistically significant. Data
were analyzed using Stata 14.0 software (StataCorp LP, College Station, TX, USA).
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3. Results
Among the 85 patients treated for Stage I glottic SCC by the Head and Neck MDT of our Institution,
74 were enrolled in the present study. Those excluded (n = 11) had already received previous head and
neck treatments (n = 4), presented with PC involvement (n = 3), had incomplete pretreatment diagnostic
data (n = 3), or did not give consent to be enrolled in the present study (n = 1). Table 1 summarizes
the study population characteristics. A total of 22 T1a (30%), 5 T1b without AC involvement (7%),
and 47 T1b with AC involvement (63%) were analyzed. The male to female ratio was 8:1 and the
median age at presentation was 68 years (mean, 67.83 ± 11.44; range, 38–90). We did not find any
statistical significance in the age categories (<50 years; 50–65 years; >65 years), or in the smoking and
alcohol habits among the three tumor categories (T1a, T1b without AC involvement, and T1b with AC
involvement). On the other hand, the CCI seemed to be slightly higher in T1b with AC involvement
(p = 0.049).
Thirty-six patients (48%) underwent TLM, whilst the remaining 38 (52%) received curative RT.
The vast majority of T1a patients (90.9%) had surgical treatment, while 66% of T1b with AC involvement
underwent RT. This treatment modality represented the preferred therapeutic approach in the presence
of AC involvement (p < 0.001). The incidence of post-treatment complications, as well as the need
for adjuvant RT after primary TLM, showed no statistically significant association with any of the
proposed T1 subcategories.
The median follow-up period was 30 months (mean, 32.09 ± 18.73 months; range, 12–79).
The three-year OS, DSS, RFS, and LFS were compared according to tumor location, extension, and
cT category.
The total number of recurrences was 17 out of 74 patients (22.9%) and salvage treatment was
represented by TLM in 7 patients out of 17 (41.2%), salvage total laryngectomy in 7 (41.2%), open
partial horizontal laryngectomy in 2 (11.7%), and RT in 1 (5.9%). The recurrence rate was significantly
higher among T1b with AC involvement (31.9%) in comparison to T1a (4.5%) and T1b without AC
involvement (20%), with a p-value of 0.028 (Table 2).
Table 1. Study population characteristics.






Number of patients 22 (30) 5 (7) 47 (63)
Male gender 21 (95.5) 4 (80.0) 42 (89.4) 0.405
Age at diagnosis
<50 years 0 1 (20.0) 4 (8.5) 0.56
50–65 years 5 (22.7) 3 (60.0) 19 (40.4)
>65 years 17 (77.3) 1 (20.0) 24 (51.1)
Charlson comorbidity index
(median (IQR)) 3 (2–5) 2 (2–2) 3 (2–4) 0.049 *
Smoking habit
Yes 13 (59.1) 3 (60.0) 31 (66.0) 0.267
No 8 (36.4) 1 (20.0) 8 (17.0)
Missing data 1 (4.6) 1 (20.0) 8 (17.0)
Alcohol abuse
Yes 3 (13.6) 1 (20.0) 8 (17.0) 0.495
No 18 (81.8) 3 (60.0) 31 (66.0)
Missing data 1 (4.6) 1 (20.0) 8 (17.0)
Disease characteristics
Tumor location
Free margin 19 (86.4) 2 (40.0) 29 (61.7) 0.015 *
Superior aspect 3 (13.6) 3 (60.0) 8 (17.0)
Inferior aspect 0 0 10 (21.3)
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Table 1. Cont.









(TLM) 20 (90.9) 0 16 (34.0) <0.001 *
Radiotherapy (RT) 2 (9.1) 5 (100.0) 31 (66.0)
Resection margin
Negative 17 (85.0) - 12 (75.0) 0.530
Positive superficial, single 1 (5.6) - 0
Positive superficial, multiple 0 - 1 (6.3)
Positive deep, single 0 - 1 (6.3)
Positive deep, multiple 0 - 1 (6.3)
Missing data 2 (10.0) 1 (6.3)
Post-treatment complications
No 15 (68.2) 2 (40.0) 35 (74.5) 0.249
Yes 7 (31.8) 3 (60.0) 12 (25.5)
Dysphagia 2 (9.1) 1 (25.0) 6 (12.8)
Dysphonia 0 1 (25.0) 0
Dyspnea 0 1 (25.0) 0
Stenosis 0 0 1 (2.1)
Granuloma 5 (22.7) 0 1 (2.1)
Adjuvant RT
No 21 (95.5) 5 (100.0) 33 (70.2) 0.83
Yes 0 0 5 (10.6)
Missing data 1 (4.6) 0 9 (19.2)
Table 2. Disease recurrence and mortality rates.






Number of patients 22 (30) 5 (7) 47 (63)
Recurrence
No 21 (95.5) 4 (80.0) 32 (68.1) 0.028 *








- - 2 (4.3)
Total laryngectomy
+/- Neck dissection - 1 (20.0) 6 (12.8)
RT - - 1 (2.1)
Disease-related
mortality 0 0 2 (4.3) 1.000
All-cause
mortality 1 (4.6) 0 2 (4.3) 1.000
In fact, T1b with AC involvement experienced 15 of 17 total recurrences (88.2%), significantly
affecting the RFS and LFS in comparison to the other two (T1a, p = 0.028 and T1b without AC
involvement, p = 0.043).
The OS was 95.5%, 100%, and 95.7% for T1a, T1b without AC involvement, and T1b with AC
involvement, respectively. The mortality rate did not show any statistically significant association
with either clinical and tumor characteristics or with the type of primary treatment. Specifically,
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disease-related mortality was found only in the T1b with AC involvement group, although without
any statistical significance (p = 1.000) (Table 3).
Table 3. Survival outcomes.
OS DSS RFS LFS
T1a 21/22 (95.5%) 22/22 (100%) 21/22 (95.5%) 22/22 (100%)
T1b without AC involvement 5/5 (100.0%) 5/5 (100%) 4/5 (80.0%) 4/5 (80.0%)
T1b with AC
involvement 45/47 (95.7%) 45/47 (95.7%) 32/47 (68.1%) 37/47 (76.6%)
p-value 1.000 1.000 0.028 * 0.043 *
OS: overall survival; DSS: disease-specific survival; RFS: recurrence-free survival; LFS: laryngectomy-free survival;
* p-value statistically significant.
According to both the uni- and multivariate analyses, the increased risk for recurrence in T1b
with AC involvement and for T1a tumors was 7.31 and 9.45 times, respectively (p-value of 0.054 and
0.030, respectively). Conversely, the risk of recurrence was comparable among patients affected by T1a
and T1b without AC involvement (p = 0.304) (Figure 4; Table 4).
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Figure 4. RFS Kaplan–Meier curves (T1b-w/: T1b with AC involvement; T1b-w/o: T1b without
AC involvement).
As reported above, the significant association between T1b with AC involvement and high
CCI was also confirmed for the recurrence risk at both uni- and multivariate analyses (p = 0.030
and p = 0.023, respectively). Again, the type of treatment did not show any statistically significant
difference in the recurrence rate among the three tumor categories considered herein in the univariate
analysis (p = 0.491) (Table 4).
The LFS showed a statistically significant difference (p = 0.043) among the three tumor classes
(Figure 5 and Table 3).
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Table 4. Univariate and multivariate analyses of risk of recurrence.














involvement 3.56 (0.22–57.01) 0.369 4.38 (0.26–73.28) 0.304
T1b with AC
involvement 7.31 (0.97–55.37) 0.054 9.45 (1.24–72.30) 0.030 *
Gender
Male Ref.
Female 1.24 (0.28–5.44) 0.772
Age at diagnosis
<50 years Ref.
50–65 years 2.00 (0.25–16.06) 0.513
>65 years 1.34 (0.17–10.74) 0.783
Charlson comorbidity
index 0.47 (0.25–0.87) 0.017 * 0.49 (0.26–0.91) 0.023 *
Smoking habit 2.49 (0.56–11.13) 0.233
Alcohol habit 2.85 (0.95–8.56) 0.062
Tumor location
Free margin Ref.
Superior aspect 0.77 (0.22–2.69) 0.678
Inferior aspect 0.36 (0.05–2.77) 0.328
Type of intervention
TLM Ref.
RT 1.40 (0.53–3.69) 0.491
Resection margin
Negative Ref.
Positive 1.74 (0.61–4.94) 0.299
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4. Discussion
Although it is widely acknowledged that the presence of AC involvement can have a negative
impact on the oncologic outcomes of early glottic SCC, the r sults so far reported in the lit r ture bout
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its predictive value have been inconsistent, and have generated much debate [19,22–25]. Even though
several reviews have analyzed this issue, none of them definitively solved the existing controversy of
the prognostic value of AC involvement [19]. In fact, the unique AC anatomical characteristics make
this laryngeal subsite a challenging area for adequate pretreatment endoscopic and imaging workup
by either CT or MR (with a high incidence of false negatives adequately assessed only intraoperatively,
after surgical resection, or at longer follow-up), difficult area for surgical resection due to laryngeal
exposure, and prone to technical radiotherapy issues at the air–tumor interface within the AC due to
its variable degree of vascularization, ossification, and three-dimensional conformation/development
further complicating its proper management [6,8].
To further elucidate the impact of AC involvement in early glottic SCC in this setting, we started
from the assumption that if the extension to the AC represents a worsening prognostic factor, it would
definitely deserve a specific T category different from the already existing categories of T1 to which it is
usually associated in terms of survival. To accomplish this purpose, we did not linger on T1 spreading
patterns or on a proper AC classification system as previously proposed by several authors [7,22].
Instead, we aimed to highlight the potential predictive value of AC involvement by differentiating
the existing T1b category, and looking for similarity in prognosis among T1a and T1b without AC
involvement (p = 0.304) (Table 4), based on our proposed tumor staging and independently for the
primary treatment chosen, either surgical (TLM) or non-surgical (RT).
Our study population presented demographics and therapeutic indications comparable to those
reported in the literature [10,12]. Even our reported recurrence rates are in accordance with the
literature results, which usually range from 17% to 24%, depending on the follow-up schedules and
modality [13,14,26]. Interestingly enough, our data confirm that one of the two T1b subcategories
(i.e., T1b with AC involvement) represents an independent prognostic factor for survival and resulted
in a significant association with a higher recurrence rate in comparison to T1a (p = 0.028). By analyzing
this prognostic impact on survival, we found a trend towards worse DSS for T1b with AC involvement,
though without a statistically significant p-value due to the relatively small sample size (Table 3;
Figure 6).
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The predictive potential of the T1b with AC involvement category was reflected by an even
more significant difference in the LFS, which was reported to be 100% in the T1a category, 80% in
the T1b without AC involvement, and 76.6% in T1b with AC involvement (p = 0.043). These values
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are also in accordance with the current literature [15–17,27,28]. Furthermore, as long as different
treatment strategies seem to result in equal clinical outcomes, the matter of post-treatment morbidity
and long-term sequelae should be emphasized even more within the decision-making process.
Interestingly, no statistically significant difference were revealed among the three tumor classes,
regardless of the respective therapeutic (surgical vs. non-surgical) modality applied, thus reflecting
the fact that tumor stage is per se an independent prognostic factor for survival and that choosing
the appropriate treatment regimen in the management of AC involvement should be guided by mere
functional considerations more than anatomical ones. Notwithstanding, an independent and specific
tumor category such as the T1b with AC involvement proposed here would play a role in alerting the
treating MDT about the potentially higher risk of suboptimal local control in such a condition.
We do believe that the present classification of T1, which does not take into proper account
the AC involvement, might not be fully consistent with the AJCC UICC staging system principles
which aim to distinguish the outcomes of tumors by a non-contradictory single prognostic language
(https://cancerstaging.org). For these reasons, we suggest that the T staging of glottic SCC should
consider AC involvement by a more detailed tumor subsite stratification. Further studies should
overcome the limitations of the present analysis, which are mainly due to a small sample size of T1b
without AC involvement (also due to their intrinsic rarity), disabling proper and significant statistics.
In addition, the application of a prospective study protocol design will give more consistency and allow
a more detailed and homogeneous diagnostic imaging acquisition, treatment modalities outcome, and
side effects analysis, which was not the main purpose of the current retrospective study.
5. Conclusions
In our study, the AC represents the glottic subsite with the greatest risk of local treatment failure
and tumor persistence after either TLM and RT [29,30]. Our proposed classification system for glottic T1
with AC involvement could represent a starting point to overcome the actual T1 staging and treatment
heterogeneity, where T1b with AC involvement could deserve a separate subcategory due to its evident
worse prognosis in comparison to T1a tumors. However, before including such an AC subclassification
system into future editions of the AJCC UICC staging system, multicenter, large-sampled cohorts
of T1 with different extensions, treated by either TLM or RT, need to be prospectively collected and
evaluated in order to confirm our preliminary data.
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